One Step Dementia Risk Test Kit
Key words:
Qankorey
Classification:
Products
Colloidal gold immunochromatography technology was used to qualitatively detect the Aβ concentration level in human urine, and the world's first AD urine test early screening tool.
Product Specifications
►First Globally
►Clinically approved
►Fast: 10 Mins have result
►Sensivity: 75.7%; Specificity: 91.03%
►Easy to use: add 100uL (4 drops) urine
►Early screening: Risk alert of Dementia
►Non-invasive: IVD detection, use fresh urine sample test
►Hypersensitivity: Detection sensitivity up to picogram level
►Accurate: The positive judgment value was 0.5ng/mL, and the detection rate was 95%
Product Name | One Step Dementia Risk Test Kit (Colloidal Gold Lateral Immunochromatography) |
Certificate | CE, NMPA, MDA |
Packing | 1pc/box, 25pcs/box, 50pcs/box |
Usage | This product is an in vitro auxiliary screening device for risk alert of dementia (including but not limited to Alzheimer's disease). It may be used to evaluate brain health status and assist doctors to decide whether further tests are required. |
Product Application
It can be applied to the regular physical examination population over 45 years old;
Family history of dementia;
Memory impairment and suspected cognitive impairment;
Cardiovascular and cerebrovascular diseases and cerebrovascular injuries (stroke, cerebral hemorrhage, cerebral infarction, etc.);
Chronic diseases (hypertension, diabetes, hyperlipidemia, etc.), snoring and homocysteine deficiency;
Anxiety, depression, bad habits (smoking and drinking, lack of exercise in the middle of obesity, long-term lack of sleep, etc.);
Recommend Products
A biotechnology company focusing on key technologies for Alzheimer's disease (AD), a global medical challenge.